Search Results
Olaparib and investigational PI3K inhibitor BKM120 combination active against ovarian
Ongoing Clinical Trials with PARP Inhibitors in Ovarian Cancer
The promising potential of PARP inhibitors in ovarian cancer
Dr. Patel on Cediranib Versus Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
Significant Factors of Clinical Outcomes With Olaparib in Patients With Ovarian Cancer
Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer
PARP Inhibition in Ovarian Cancer
Dr. Pothuri on PARP Inhibitors for Ovarian Cancer
Dr. Matulonis on Toxicities With Olaparib for Patients With Ovarian Cancer
Dr. Ledermann Discusses Olaparib in Ovarian Cancer
Dr. Aghajanian Discusses PARP Inhibitors for the Treatment of Ovarian Cancer
Olaparib and bevacizumab: On the horizon for treating ovarian cancer
